Finding a Safe Dose of a New Drug for Some Types of Solid Tumors
LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
LMB-100 is a lab-created protein that targets mesothelin. It is being tested against pancreatic cancer and other solid tumors in a clinical trial.
Researchers are creating personalized vaccines to stimulate a pancreatic cancer patient’s immune system after surgery and chemotherapy.
The OncoSil radiotherapy implant device is being tested on pancreatic cancer in a clinical trial that combines it with standard chemotherapy.
A clinical trial tests the safety and effectiveness of tumor-associated antigen-specific cytotoxic T lymphocytes, which target specific tumor proteins.
A new clinical trial adds vitamin D to standard of care chemotherapy before surgery, to make pancreatic cancer tumors more removable.
Relatives of pancreatic cancer patients or people who carry certain mutations can participate in an early detection clinical trial.
Researchers are testing a drug combination that adds immunotherapy to standard drugs used to treat pancreatic cancer and an antimalarial drug.
A clinical trial looks for the best dose of an experimental drug to combat the mouth sores that are a side effect of radiation treatment.
Researchers are testing a new monoclonal antibody to see if it helps patients with pancreatic tumors that can be surgically removed.
In a clinical trial, the new drug sapanisertib is being tested for its effectiveness against pancreatic neuroendocrine tumors (PNETs).